These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 22900354)
1. Role of protein tyrosine kinase inhibitors in cancer therapeutics. Bhise SB; Nalawade AD; Wadhawa H Indian J Biochem Biophys; 2004 Dec; 41(6):273-80. PubMed ID: 22900354 [TBL] [Abstract][Full Text] [Related]
2. Imatinib as a paradigm of targeted therapies. Druker BJ Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887 [TBL] [Abstract][Full Text] [Related]
3. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia]. Usui N Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317 [TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Tibes R; Trent J; Kurzrock R Annu Rev Pharmacol Toxicol; 2005; 45():357-84. PubMed ID: 15822181 [TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132 [TBL] [Abstract][Full Text] [Related]
12. [Imatinib--a new perspective in the treatment of tumors]. Klener P; Klamová H Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894 [TBL] [Abstract][Full Text] [Related]
14. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Eck MJ; Manley PW Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274 [TBL] [Abstract][Full Text] [Related]
15. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. Cortes J; Kantarjian H Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047 [TBL] [Abstract][Full Text] [Related]
16. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. George D Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804 [TBL] [Abstract][Full Text] [Related]
17. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. Johnson FM; Saigal B; Donato NJ J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238 [TBL] [Abstract][Full Text] [Related]
18. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Hess-Stumpp H; Haberey M; Thierauch KH Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376 [TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Kantarjian HM; Talpaz M Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802 [TBL] [Abstract][Full Text] [Related]
20. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase. Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]